1-丁氧基吡咯烷-2,5-二酮 | 915379-05-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 1-丁氧基吡咯烷-2,5-二酮
• 英文名称: 1-Butoxy-pyrrolidine-2,5-dione
• 英文别名: 1-Butoxypyrrolidine-2,5-dione
• CAS: 915379-05-4
• 化学式: C₈H₁₃NO₃
• 分子量: 171.196
• InChiKey: RISNFTILCYTNOD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.4
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.75
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-丁氧基吡咯烷-2,5-二酮 在 盐酸 作用下， 生成 O-丁基羟胺盐酸盐
  参考文献：
  名称：

  2-（1-烷氧基亚氨基-2,2,2-三氟乙基）-5-三甲基甲硅烷基呋喃的合成和立体异构化

  摘要：

  DOI：

  10.1007/s10593-005-0211-7
• 作为产物：
  描述：

  N-羟基丁二酰亚胺 、 alkaline earth salt of/the/ methylsulfuric acid 生成 1-丁氧基吡咯烷-2,5-二酮
  参考文献：
  名称：

  2-（1-烷氧基亚氨基-2,2,2-三氟乙基）-5-三甲基甲硅烷基呋喃的合成和立体异构化

  摘要：

  DOI：

  10.1007/s10593-005-0211-7

文献信息

• [EN] FGF RECEPTOR-ACTIVATING 3-O-ALKYL OLIGOSACCHARIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF<br/>[FR] 3-O-ALKYL-OLIGOSACCHARIDES ACTIVATEURS DE RÉCEPTEUR FGF, PRÉPARATION DE CEUX-CI ET UTILISATION THÉRAPEUTIQUE DE CEUX-CI
  申请人：SANOFI SA

  公开号：WO2012101605A1

  公开（公告）日：2012-08-02

  The invention relates to the FGF receptor-activating oligosaccharides corresponding to formula (I) in which R1 represents an optionally substituted -O-alkyl group, R2 represents a hydroxyl group or an -O-alkyl group, R3, R5, R6, R7 and R8 represent -OSO3- or hydroxyl groups, R4 represents an NH-CO-alkyl or -O-alkyl group, R represents an -O-alkyl group, and n and m, which may be identical to or different from one another, represent integers equal to 0 or 1. Method for the preparation thereof and therapeutic use thereof.

  该发明涉及与式（I）中R1代表可选择地取代的-O-烷基基团，R2代表羟基或-O-烷基基团，R3、R5、R6、R7和R8代表-OSO3-或羟基，R4代表NH-CO-烷基或-O-烷基基团，R代表-O-烷基基团，n和m，可以相同也可以不同，代表整数0或1的FGF受体激活寡糖。其制备方法和治疗用途。
• FGF RECEPTOR-ACTIVATING 3-O-ALKYL OLIGOSACCHARIDES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
  申请人：SANOFI

  公开号：EP2668198A1

  公开（公告）日：2013-12-04
• CROSSLINKED GELS COMPRISING POLYALKYLENEIMINES, AND THEIR USES AS MEDICAL DEVICES
  申请人：HyperBranch Medical Technology, Inc.

  公开号：US20170049924A1

  公开（公告）日：2017-02-23

  One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Treatment of the polyethyleneimine with a cross-linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer. In certain instances, the polyethyleneimine is mixed with a second polymer, such as a polyethylene glycol containing nucleophilic groups. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneimine bearing electrophilic groups with a cross-linking reagent containing nucleophilic groups. In certain instances, the electrophilic groups on the polyalkyleneimine are activated esters, such as N-hydroxy succinimide ester. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneimine bearing photopolymerizable groups with ultraviolet or visible light. Compositions used to seal the wound which contain PEI or a derivative of PEI are found to adhere tightly to the tissue. Other aspects of the present invention relate to methods of filling a void of a patient or adhering tissue. In certain instances, the methods use a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Another aspect of the present invention relates to a polymeric composition formed by exposing a polyalkyleneimine to an activated polyalkylene glycol. In certain instances, the composition is attached to mammalian tissue.
• US7927596B2
  申请人：——

  公开号：US7927596B2

  公开（公告）日：2011-04-19
• US9878066B2
  申请人：——

  公开号：US9878066B2

  公开（公告）日：2018-01-30